XS 004 - XellSmart Biomedical (Suzhou)
Alternative Names: XS-004 - XellSmart Biomedical (Suzhou); XS_004Latest Information Update: 29 Dec 2023
At a glance
- Originator XellSmart Biomedical (Suzhou)
- Class Antineoplastics; Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 Dec 2023 Preclinical trials in Solid tumours in China (Parenteral), prior to December 2023 (XellSmart Biomedical (Suzhou) pipeline, December 2023)